Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by alixx11on Aug 29, 2013 2:03pm
147 Views
Post# 21706967

RE:RE:Financials...

RE:RE:Financials...MM,
 
My comment about the unlikelihood of getting as sweet a deal as we had with ARZ is mostly based on a few key points. I think it’s unlikely that we’ll see the gold price highs of 2011 again. And even though I think the gold price will rise from where it is now, I don’t think we’ll see as much interest in funding juniors as before, or at the very least more caution and tougher negotiations will be more the norm... Basically, I just think it will be a tougher environment for juniors to negotiate good JVs than it was in near-past...
 
Having said that, you raise valid points which can’t be ignored. Since the ARZ deal (and we were only 2/3 complete), the ounces have doubled. And they do have reasonable cash in the bank (although, as I said, not enough to get real aggressive on their own). Matt Zylstra, the last real analyst to cover NOX, was concerned over the strip ratio (which he hoped could be reduced by proving out additional ounces with infill drilling).
 
Now even though we may disagree about how good a deal we can get, I want to make clear that I don’t believe we need as good a deal as we had. Even a deal 75% as good as we had, with a solid partner (not a Hecla, more an Osisko) would likely be enough to get us back up where we should be.
 
The key in my mind is finding a good partner soon, and getting a fair deal...
 
Ax.
<< Previous
Bullboard Posts
Next >>